Drug Trial Radar · NCT00548405
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
Last checked: Nov 20, 2026Latest source record: Apr 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
840
Actual
Start
Oct 2007
Primary completion
Sep 2011
Study completion Sep 2011
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Bayer
- First posted
- Oct 24, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to establish the efficacy and safety of two different doses of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous interferon beta-1a (Rebif®). The study enrolled participants who had received an adequate trial of disease-modifying therapies but experienced at least 1 relapse during prior treatment, and who met a minimum severity of disease as measured by magnetic resonance imaging (MRI). Participants had monthly laboratory tests and comprehensive testing every 3 months.
Conditions
- Multiple Sclerosis, Relapsing-Remitting
Interventions
Alemtuzumab 12 mgBiological
Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
Alemtuzumab 24 mgBiological
Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.
Interferon beta-1aBiological
Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Sustained Accumulation of Disability (SAD)Time frame: Up to 2 years
- Annualized Relapse RateTime frame: Up to 2 years
Locations
191 sites in 23 countries. Site status is shown where the registry gives one.
North Central Neurology Associates, P.C.
Cullman, Alabama
Barrow Neurological Institute, St. Joseph's Hospital and Medical Center
Phoenix, Arizona
Hope Research Institute
Phoenix, Arizona
Mayo Clinic Arizona, Department of Neurology
Scottsdale, Arizona
Northwest NeuroSpecialists, PLLC
Tucson, Arizona
East Bay Physicians Medical Group/Sutter East Bay Medical Foundation
Berkeley, California
Neurology Center of North Orange County
La Habra, California
Department of Neurology, Keck School of Medicine, University of Southern California
Los Angeles, California
Neuro-Therapeutics Inc.
Pasadena, California
Neuro-Therapeutics, Inc
Pasadena, California
University of California, Davis Medical Center
Sacramento, California
Stanford University School of Medicine
Stanford, California
University of Colorado Hospital, Anschutz Outpatient Pavilioin
Aurora, Colorado
Neurological Consultants
Denver, Colorado
Advanced Neurosciences Research
Fort Collins, Colorado
Yale University
New Haven, Connecticut
George Washington University Medical Faculty Associates
Washington D.C., District of Columbia
University of Florida Neuroscience Institute
Jacksonville, Florida
Neurology Associates, P.A.
Maitland, Florida
Neurological Associates
Pompano Beach, Florida
Negroski, Stein, Sutherland and Hanes Neurology
Sarasota, Florida
Axiom Clinical Research of Florida
Tampa, Florida
University of South Florida, Department of Neurology
Tampa, Florida
Emory University, Department of Neurology
Atlanta, Georgia
Shepherd Center, Inc.
Atlanta, Georgia
Idaho Falls Multiple Sclerosis Center, PLLC
Idaho Falls, Idaho
University of Chicago Medical Center, Department of Neurology
Chicago, Illinois
Consultants in Neurology, Ltd
Northbrook, Illinois
Fort Wayne Neurological Center
Fort Wayne, Indiana
Indiana University School of Medicine, Department of Neurology
Indianapolis, Indiana
Josephson Wallack Munshower Neurology P.C.
Indianapolis, Indiana
Iowa Health Physicians
Des Moines, Iowa
Ruan Neurology Clinic and Research Center
Des Moines, Iowa
University of Kansas Medical Center, Department of Neurology
Kansas City, Kansas
MidAmerica Neuroscience Institute
Lenexa, Kansas
Associates in Neurology, PSC
Lexington, Kentucky
University of Louisville Research Foundation
Louisville, Kentucky
Louisiana State University Health Sciences Center
Shreveport, Louisiana
Caritas St. Elizabeth's Medical Center
Boston, Massachusetts
Partners Multiple Sclerosis Center/Brigham and Women's Hospital
Boston, Massachusetts
Showing 40 of 191 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.